Marksans Pharma Ltd

Stage 3 · Topping · week 1

As of 20 Nov 2026, Marksans Pharma is in Stage 3, the topping phase, now in its first week (since 16 Nov 2026). It closed at ₹291, 16.2% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the Uni… More about the company

₹291.2
Close, 20 Nov 2026
-2.64% on the day
₹13,195 Cr · Mid cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

MARKSANS's uptrend is tiring: in its first week into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 91 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is MARKSANS early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 16w
S2 39w
S4 15w
S2 25w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 8w → S3 4w → S2 16w → S3 7w → S2 39w → S3 7w → S4 11w → S1 11w → S4 15w → S1 9w → S4 13w → S1 4w → S2 25w → S3 1w current
Total tracked: 168 weeks across 14 stage runs.

MARKSANS among Pharmaceuticals27th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…27MARKSANSStage 3 · wk 191−2.3%
vs 52W High
-16.2%
₹156.9 lo₹347.6 hi
16.2% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 1
1w13w26w
Week 1, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
16.7%
200 DMA: ₹249.5 · rising
The stock still holds above its 200-day average, but the trend has flattened. A close below the line would add to the Stage 4 risk.
Rel Volume
0.50x
vs 50-day avg
Volume was well below average. Quiet sessions say little in a topping stock. Volume on the down days matters more.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-2.3%
3M
-11.0%
6M
+33.9%
YTD
+61.5%
1Y
+54.6%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →

Mutual fund holdings

Held by 20 mutual funds in portfolios to October 2026: 13 active funds and 7 index funds and ETFs.

In October, among active funds: 2 increased, 3 opened a new position and 4 reduced.

5 increased or opened4 reduced or exited
Largest active holders, by weight in the fund
All 20 funds and what each did in October

Mutual funds holding MARKSANS: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 7 Oct 2026
Last appeared 1 Sep 2026
Last appeared 21 May 2026
4 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S3
Wk 1 · Vol 0.50x
2026-11-19S3
Wk 1 · Vol 0.39x
2026-11-18S3
Wk 1 · Vol 0.77x
2026-11-17S3
Wk 1 · Vol 0.46x
2026-11-16S32→3
Wk 1 · Vol 0.60x
2026-11-13S2
Wk 25 · Vol 0.88x
2026-11-12S2
Wk 24 · Vol 1.06x
2026-11-11S2
Wk 24 · Vol 0.62x
2026-11-09S2
Wk 24 · Vol 0.41x
2026-11-06S2
Wk 24 · Vol 0.67x
2026-11-05S2
Wk 24 · Vol 1.05x
2026-11-04S2
Wk 23 · Vol 3.09x
Moving averages & range
50 DMA
₹315.6
200 DMA
₹249.5
52W High
₹347.6
52W Low
₹156.9
5D Low
₹291.2
Resistance levels (recent highs)
20d High
₹320
60d High
₹347.6
120d High
₹347.6
250d High
₹347.6
Next resistance
+9.9%
to 20d High
P/E (TTM)
25.8
Forward 22.8
Earnings Growth (YoY)
+43.3%
Revenue +30.5%
ROE
+18.6%
Profit margin +16.5%
Dividend Yield
0.28%
P/B 4.3

Marksans Pharma: quick answers

What stage is Marksans Pharma in?

As of 20 Nov 2026, Marksans Pharma (MARKSANS) is in Stage 3, the topping phase. It entered Stage 3 on 16 Nov 2026 and is in its first week there. What the four stages mean

Is Marksans Pharma in an uptrend?

Its uptrend has stalled. Marksans Pharma is in Stage 3, the topping phase that follows an advance. It trades 16.7% above its 200-day average, which is rising.

How far is Marksans Pharma from its 52-week high?

Marksans Pharma closed at ₹291 on 20 Nov 2026, 16.2% below its 52-week high of ₹348. Its 52-week low is ₹157.

How has Marksans Pharma performed over the past year?

As of 20 Nov 2026, Marksans Pharma is up 54.6% over the past year and up 61.5% so far in 2026.

Which sector and industry is Marksans Pharma in?

Marksans Pharma is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.